BioLineRx Ltd. Announces Results From Phase 1/2 Study For Celiac Treatment
7/16/2014 9:29:33 AM
JERUSALEM--(BUSINESS WIRE)--BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today unblinded results from its Phase 1/2 study for BL-7010, a novel polymer for the treatment of celiac disease.
Help employers find you! Check out all the jobs and post your resume.
comments powered by